Latest News

In case you missed it, this week we had news on the commercial launch of cosibelimab-ipdl, dupilumab in pediatric AD, a phase 3 trial of lebrikizumab in nummular eczema, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.

Renata Block, DMSc, MMS, PA-C, explores how AI could transform dermatology with insights from Dr. GPT on integration, equity, and the future of patient care.

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.

Almirall initiates a pivotal phase 3 trial for lebrikizumab, targeting nummular eczema and aiming to enhance treatment options for this challenging condition.

Heap discusses promising phase 3 results for zasocitinib, an oral TYK2 inhibitor, showcasing its efficacy and safety in psoriasis therapy.

Discover how auricular acupuncture could enhance facial aesthetics, offering non-invasive rejuvenation with rapid results and minimal downtime for wrinkle reduction.

Topical roflumilast 0.3% cream shows promise in reducing lesions and symptoms of mild hidradenitis suppurativa (HS), offering a well-tolerated treatment option.

Explore the complexities of managing HS through real-world case studies moderated by Afsaneh Alavi, MD.

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.